City of Hope

City of Hope, a NCI-designated Comprehensive Cancer Center

Page Title

Skip Navigation

Global Navigation



Border Border
  
  PROFILE 
The following is a list of available studies directed by  Przemyslaw Twardowski, MD  
Search results:  8  Clinical trial(s) found  (Page 1 of 1 )
Results per page: 25 50 100 All 1-8 Trials Jump to page:

COH Protocol Number: 17113 ClinicalTrials.gov Number: NCT03072238

Principal Investigator: Przemyslaw Twardowski, MD
Sponsor: Industrial

Title:  A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative To Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer

COH Protocol Number: 17039 ClinicalTrials.gov Number: NCT03012321

Principal Investigator: Przemyslaw Twardowski, MD
Sponsor: Institutional

Title:  A Randomized Phase II Trial of Abiraterone, Olaparib, or Abiraterone + Olaparib in Patients with Metastatic Castration-Resistant Prostate Cancer with DNA Repair Defects

COH Protocol Number: 16413 ClinicalTrials.gov Number: NCT02987543

Principal Investigator: Przemyslaw Twardowski, MD
Sponsor: Industrial

Title:  A Phase III, Open Label, Randomized Study to Assess the Efficacy and Safety of Olaparib (Lynparza™) Versus Enzalutamide or Abiraterone Acetate in Men with Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment with a New Hormonal Agent and Have Homologous Recombination Repair Gene Mutations (PROfound)

COH Protocol Number: 16397 ClinicalTrials.gov Number: NCT03016312

Principal Investigator: Przemyslaw Twardowski, MD
Sponsor: Industrial

Title:  A Phase III, Multicenter, Randomized Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination with Enzalutamide Versus Enzalutamide Alone in Patients With Metastatic Castration-Resistant Prostate Cancer After Failure of an Androgen Synthesis Inhibitor and Failure of, Ineligibility for, or Refusal of a Taxane Regimen

COH Protocol Number: 16358 ClinicalTrials.gov Number: NCT03148795

Principal Investigator: Przemyslaw Twardowski, MD
Sponsor: Industrial

Title:  A Phase 2, Open-Label, 2-Arm, Response Rate Study of Talazoparib in Men With DNA Repair Defects and Metastatic Castration-Resistant Prostate Cancer Who Previously Received Taxane-Based Chemotherapy and Progressed on at Least 1 Novel Hormonal Agent (Enzalutamide and/or Abiraterone acetate and Prednisone)

COH Protocol Number: 16328 ClinicalTrials.gov Number: NCT02799602

Principal Investigator: Przemyslaw Twardowski, MD
Sponsor: Industrial

Title:  A Randomized, Double-blind, Placebo-Controlled Phase III Study of ODM-201 Versus Placebo in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Patients with Metastatic Hormone-Sensitive Prostate Cancer

COH Protocol Number: 16126

Principal Investigator: Przemyslaw Twardowski, MD
Sponsor: Institutional

Title:  Assessment of Myeloid Derived Suppressor Cells (MDSC), in Blood of Patients with Localized or Recurrent or Metastatic Prostate Cancer

COH Protocol Number: 16047 ClinicalTrials.gov Number: NCT02814669

Principal Investigator: Przemyslaw Twardowski, MD
Sponsor: Industrial

Title:  A Phase Ib, Open-Label Study of the Safety and Tolerability of Atezolizumab in Combination with Radium-223 Dichloride in Patients with Castrate-Resistant Prostate Cancer Who Have Progressed Following Treatment with an Androgen Pathway Inhibitor

 
Results per page: 25 50 100 All 1-8 Trials Jump to page:

 
 
  
NCI CCC LogoCity of Hope, An NCI-designated Comprehensive Cancer Center, is an innovative biomedical research, treatment and educational institution dedicated to the prevention and cure of cancer and other life-threatening illness.
Best Of logoCity of Hope has been named one of "America's Best Hospitals" in cancer and gynecology by U.S. News & World Report. Read more here...
NCI CCC LogoThe National Comprehensive Cancer Network (NCCN), a not-for-profit alliance of 21 of the world’s leading cancer centers, is dedicated to improving the quality and effectiveness of care provided to patients with cancer.
Best Of logoWe subscribe to the HONcode of the Healthcare on the Net Foundation.